Sector News

Lilly deepens research ties in China with biotech deal

December 12, 2021
Life sciences

Lilly’s deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather than as a means of accessing the second-largest market for prescription drugs.

In recent years, Amgen, Pfizer and Seagen have struck partnerships with, or invested in China-based biotechs, while AstraZeneca set up a new R&D center in Shanghai to, among other things, better collaborate with companies there. The investment has come as Chinese biotechs have taken advantage of new rules for stock listings in Hong Kong to raise record-setting sums.

Amgen’s 2019 partnership with Beigene, which has a market capitalization of $30 billion on Nasdaq, was the most notable, both by financial value and for the number of clinical-stage drugs involved.

Lilly, too, has dipped its toes into China-based biotech research. In 2015, the drugmaker grabbed partial rights to a cancer immunotherapy developed by Innovent Biologics. That drug, now known as Tyvyt, has since been approved in China for two types of lymphoma and could be cleared for lung cancer as well. Last year, Lilly paid $200 million to broaden the partnership. READ MORE

By Ned Pagliarulo

Source: biopharmadive.com

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach